PTSD awareness day and earnings update
SUMMARY
Tonix recently held a post-traumatic stress disorder (PTSD) awareness day to highlight the current standards of care, the unmet medical need of the disease as well as the development plan for TNX-102 SL to treat it. The first Phase III trial in military-related PTSD will enroll up to 550 patients and will have one to two interim analyses, which would allow for early stoppage due to efficacy or a sample size adjustment. The trial is expected to start in Q117, with the first interim analyses expected in H217. A second trial in predominantly civilian PTSD is expected to follow.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Edison Investment Research
Leading International Investment Research
Price Chart(Sign Up to Access)
- PTSD awareness day and earnings update01 Dec 2016
x